Markets
Why Is Lilly Paying Nearly $3 Billion for a Phase 1 Graves' Drug?
Lilly is buying Merida for up to $2.875 billion, betting a Phase 1 autoantibody degrader can treat Graves' without broad immune suppression.
Newsletter
The week in pipeline, markets, policy, and science — in your inbox.
Alpha Tau Is Building the Local Answer to Pancreatic Cancer’s Systemic Breakthrough
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Daraxonrasib Approval Shifts Pancreatic Oncology from Cytotoxic Care to RAS-Targeted Precision
The FDA's landmark approval of Revolution Medicines' daraxonrasib (Rasonque) introduces the first multi-selective RAS(ON) tri-complex inhibitor for metastatic pancreatic adenocarcinoma, doubling overall survival over standard chemotherapy.
Why Amgen's GIP Blockade Still Trades at a Discount to Dual Agonists
MariTide delivered up to about 20% mean weight loss at 52 weeks without a plateau, then Amgen lost about $7 billion in market value. The remaining fight is GIP direction, first-dose gut burden, and conjugate manufacturing cost.
Why Bone Trauma Still Favors Hydrocodone Over Suzetrigine
Suzetrigine beat placebo on SPID48 in both pivotal acute-pain trials, then failed the superiority test against hydrocodone/acetaminophen, including a statistically significant loss in bunionectomy.
Roche Bets $190 Million Upfront on Hanmi's Muscle-Sparing Obesity Peptide
The $2.3 billion licensing deal for Phase 1 asset HM17321 targets a core drawback of current GLP-1 therapies: the loss of lean skeletal muscle alongside fat.
Brain Shuttle Platforms Tackle the Blood-Brain Barrier for Genetic Medicines
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.